APTOSE BIOSCIENCES INC (APTO) Stock Price, Quote, News and Overview
NASDAQ:APTO - Nasdaq - CA03835T3091 - Common Stock - Currency: USD
APTO Quote, Performance and Key Statistics
APTOSE BIOSCIENCES INC
NASDAQ:APTO (2/4/2025, 8:26:59 PM)
Premarket: 0.188 +0.01 (+4.39%)0.1801
+0 (+2.21%)
The current stock price of APTO is 0.1801 USD. In the past month the price decreased by -23.72%. In the past year, price decreased by -91.13%.
APTO Latest News, Press Releases and Analysis
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial ...
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Rumble Inc.
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Positive Decision by Nasdaq Hearings Panel ...
APTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About APTO
Company Profile
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Company Info
APTOSE BIOSCIENCES INC
251 Consumers Rd Suite 1105
North York ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 35
Company Website: https://aptose.com/
Investor Relations: https://www.aptose.com/investors
Phone: 16474799828
APTO FAQ
What is the stock price of APTO?
The current stock price of APTO is 0.1801 USD.
What is the symbol for APTOSE BIOSCIENCES INC stock?
The exchange symbol of APTOSE BIOSCIENCES INC is APTO and it is listed on the Nasdaq exchange.
On which exchange is APTO stock listed?
APTO stock is listed on the Nasdaq exchange.
Is APTO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for APTO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of APTO.
Does APTO stock pay dividends?
APTO does not pay a dividend.
What is the Price/Earnings (PE) ratio of APTO?
APTO does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.97).
What is the Short Interest ratio of APTO stock?
The outstanding short interest for APTO is 8.03% of its float.
APTO Technical Analysis
APTO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APTO. APTO may be in some trouble as it scores bad on both profitability and health.
APTO Financial Highlights
Over the last trailing twelve months APTO reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by 62.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to APTO. The Buy consensus is the average rating of analysts ratings from 8 analysts.